Wei Jie Chen

Wei Jie Chen

Auto-generated profile, based on publicly available information

Wei Jie Chen

Laboratory for Gynecological Oncology, Department of Biomedicine, Women’s Hospital, University of Basel, Hebelstrasse 20, Room 420, Basel, CH 4031, Switzerland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FCFeng-Feng Cai
Feng-Feng Cai
CKCorina Kohler
Corina Kohler
BZBei Zhang
Bei Zhang
MWMing-Hong Wang
Ming-Hong Wang
WCWei-Jie Chen
Wei-Jie Chen
XZXiao-Yan Zhong
Xiao-Yan Zhong
Both genetic and epigenetic alterations can control the progression of cancer. Genetic alterations are impossible to reverse, while epigenetic alterations are reversible. This advantage suggests that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. Some DNA methylation inhibitors and histone deacetylation inhibitors are approved by the US Food and Drug Administration as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer.

1 December 2011
Verified
Journal Article
Closed access
FCFeng Feng Cai
Feng Feng Cai
CKCorina Kohler
Corina Kohler
BZBei Zhang
Bei Zhang
WCWei Jie Chen
Wei Jie Chen
ZBZeinab Barekati
Zeinab Barekati
XZXiao Yan Zhong
Xiao Yan Zhong